Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
🙌 It's Here: the Only Stock Screener You'll Ever Need Get Started
Abbott halts EleCare output from plant at center of baby formula shortage
Published Jun 15, 2022 11:51PM ET
Updated Jun 16, 2022 03:57PM ET
© Reuters. FILE PHOTO: The Abbott Laboratories facility where dozens of recalled types of powdered baby formulas were made leading to production being halted at the location in Sturgis, Michigan, U.S., May 20, 2022. Picture taken with a drone. REUTERS/Eric Cox/File
(Reuters) - Abbott Laboratories (NYSE:ABT) has stopped production of the EleCare specialty baby formula at its plant in southwestern Michigan after thunderstorms and heavy rains flooded parts of the facility.
The pause announced on Wednesday marked the latest setback for the recently reopened Sturgis plant, which has been at the center of a baby formula shortage in the United States.
The company has notified the U.S. Food and Drug Administration (FDA) and said the incident would likely delay the production and distribution of the infant formula for a few weeks. EleCare formula is meant for children and babies who cannot tolerate intact protein or may have protein allergies.
Abbott, whose shares were trading 2.6% lower on Thursday, had reopened the plant on June 4 after a product recall and months-long shutdown due to reports of bacterial infections in infants who consumed products made at the facility.
The company, which was the biggest U.S. supplier of powder infant formula before the recall, said in a statement it had enough existing supply to meet current needs.
It plans to resume production of EleCare once the plant is re-sanitized and said it would work to restart production of Similac "as soon as possible".
At a briefing, White House spokesperson Karine Jean-Pierre said the halt in production was "disappointing", adding that the government's focus will continue to be on ramping up production and increasing supply of baby formula.
"We can't control their (Abbott) timeline ... making sure that American families only have access to safe formula. That is the focus for us."
FDA Commissioner Robert Califf said that once Abbott has a reopening plan, the agency would go to the facility to ensure a swift production restart of "safe and quality" products.
Meanwhile, Abbott and other producers continue to make formula at "higher-than-average rates," he said.
"This means that the total amount of formula available, even before the Sturgis plant is back in production, exceeds the demand for formula prior to the recall," Califf said on Twitter (NYSE:TWTR).
Related Articles
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.